De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Ligand Pharmaceuticals Toekomstige groei
Future criteriumcontroles 4/6
De verwachting is dat Ligand Pharmaceuticals de winst en omzet met respectievelijk 25.6% en 18.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 24.7% per jaar.
Belangrijke informatie
24.2%
Groei van de winst
26.4%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.8% |
Inkomstengroei | 17.4% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 02 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 216 | 99 | 92 | 158 | 3 |
12/31/2025 | 181 | 65 | 79 | 129 | 5 |
12/31/2024 | 157 | 54 | 32 | 88 | 6 |
6/30/2024 | 133 | 42 | -4 | 48 | N/A |
3/31/2024 | 118 | 96 | -17 | 34 | N/A |
12/31/2023 | 131 | 54 | -4 | 50 | N/A |
9/30/2023 | 154 | 21 | 90 | 95 | N/A |
6/30/2023 | 180 | 41 | 99 | 108 | N/A |
3/31/2023 | 204 | 51 | 104 | 120 | N/A |
12/31/2022 | 196 | -5 | 120 | 138 | N/A |
9/30/2022 | 183 | 23 | 95 | 112 | N/A |
6/30/2022 | 188 | 27 | 97 | 112 | N/A |
3/31/2022 | 223 | 45 | 110 | 120 | N/A |
12/31/2021 | 242 | 76 | 71 | 79 | N/A |
9/30/2021 | 275 | 68 | 45 | 52 | N/A |
6/30/2021 | 252 | 48 | 37 | 44 | N/A |
3/31/2021 | 208 | 39 | 42 | 48 | N/A |
12/31/2020 | 164 | 7 | 51 | 55 | N/A |
9/30/2020 | 143 | -16 | 41 | 47 | N/A |
6/30/2020 | 126 | -25 | 24 | 28 | N/A |
3/31/2020 | 110 | -61 | -60 | -58 | N/A |
12/31/2019 | 120 | 629 | 781 | -29 | N/A |
9/30/2019 | 153 | 594 | 812 | 11 | N/A |
6/30/2019 | 174 | 677 | 846 | 44 | N/A |
3/31/2019 | 239 | 764 | 980 | 179 | N/A |
12/31/2018 | 251 | 143 | 183 | 194 | N/A |
9/30/2018 | 242 | 179 | 198 | 193 | N/A |
6/30/2018 | 230 | 120 | 196 | 193 | N/A |
3/31/2018 | 168 | 53 | N/A | 130 | N/A |
12/31/2017 | 141 | 13 | N/A | 89 | N/A |
9/30/2017 | 129 | 16 | N/A | 78 | N/A |
6/30/2017 | 117 | 9 | N/A | 69 | N/A |
3/31/2017 | 109 | -3 | N/A | 69 | N/A |
12/31/2016 | 109 | -2 | N/A | 61 | N/A |
9/30/2016 | 92 | 7 | N/A | 56 | N/A |
6/30/2016 | 88 | 205 | N/A | 48 | N/A |
3/31/2016 | 87 | 235 | N/A | 47 | N/A |
12/31/2015 | 72 | 230 | N/A | 42 | N/A |
9/30/2015 | 74 | 231 | N/A | 38 | N/A |
6/30/2015 | 71 | 33 | N/A | 32 | N/A |
3/31/2015 | 63 | 11 | N/A | 26 | N/A |
12/31/2014 | 65 | 12 | N/A | 21 | N/A |
9/30/2014 | 56 | 7 | N/A | 22 | N/A |
6/30/2014 | 54 | 8 | N/A | 18 | N/A |
3/31/2014 | 53 | 10 | N/A | 21 | N/A |
12/31/2013 | 49 | 9 | N/A | 21 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei LGND ( 25.6% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van LGND ( 25.6% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).
Hoge groeiwinsten: De winst van LGND zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van LGND ( 18.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van LGND ( 18.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van LGND naar verwachting over 3 jaar hoog zal zijn